Patents by Inventor Randy D. Gascoyne

Randy D. Gascoyne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Evaluation of mantle cell lymphoma and methods related thereto
    Patent number: 11725248
    Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 15, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg, Oregon Health & Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and Research
    Inventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
  • Method for subtyping lymphoma types by means of expression profiling
    Patent number: 11574704
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 7, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs, Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • BIOMARKERS FOR NON-HODGKIN LYMPHOMAS AND USES THEREOF
    Publication number: 20220282336
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
    Type: Application
    Filed: May 9, 2022
    Publication date: September 8, 2022
    Inventors: Ryan D. MORIN, Marco A. MARRA, Andrew J. MUNGALL, Martin HIRST, Maria MENDEZ-LAGO, Randy D. GASCOYNE, Joseph M. CONNORS
  • Biomarkers for non-hodgkin lymphomas and uses thereof
    Patent number: 11326212
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: May 10, 2022
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Ryan D. Morin, Marco A. Marra, Andrew J. Mungall, Martin Hirst, Maria Mendez-Lago, Randy D. Gascoyne, Joseph M. Connors
  • Survival predictor for diffuse large B cell lymphoma
    Patent number: 11028444
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 8, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • METHOD FOR SUBTYPING LYMPHOMA TYPES BY MEANS OF EXPRESSION PROFILING
    Publication number: 20200143906
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 7, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health & Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HF
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs (Deceased), Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • Method for subtyping lymphoma types by means of expression profiling
    Patent number: 10607717
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: March 31, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health and Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HF
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs, Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO
    Publication number: 20190153539
    Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.
    Type: Application
    Filed: April 20, 2017
    Publication date: May 23, 2019
    Applicants: The United States of America, as represented by the secretary, Dep. of Health and Human Service, British Columbia Cancer Agency Branch, Julius-Maximilians - University of Würzburg, Oregon Health and Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, Board of Regents of the University of Nebraska, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and Research
    Inventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
  • BIOMARKERS FOR NON-HODGKIN LYMPHOMAS AND USES THEREOF
    Publication number: 20190153540
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
    Type: Application
    Filed: October 1, 2018
    Publication date: May 23, 2019
    Inventors: Ryan D. MORIN, Marco A. MARRA, Andrew J. MUNGALL, Martin HIRST, Maria MENDEZ-LAGO, Randy D. GASCOYNE, Joseph M. CONNORS
  • Biomarkers for non-hodgkin lymphomas and uses thereof
    Patent number: 10113199
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods of classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the same for a mutation in one or more biomarkers.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: October 30, 2018
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Ryan D. Morin, Marco A. Marra, Andrew J. Mungall, Martin Hirst, Maria Mendez-Lago, Randy D. Gascoyne, Joseph M. Connors
  • SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA
    Publication number: 20180245165
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Arizona Regents on Behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • Survival predictor for diffuse large B cell lymphoma
    Patent number: 9970059
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 15, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • METHOD FOR SUBTYPING LYMPHOMA TYPES BY MEANS OF EXPRESSION PROFILING
    Publication number: 20160283653
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 29, 2016
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs (Deceased), Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • Biomarkers for non-hodgkin lymphomas and uses thereof
    Patent number: 9045801
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: June 2, 2015
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Ryan D. Morin, Marco A. Marra, Randy D. Gascoyne, Joseph M. Connors
  • SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA
    Publication number: 20150132297
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary and Westfield College, University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat De Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Wuerzburg
    Inventors: Lisa Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • Biomarkers for Non-Hodkin Lymphomas and Uses Thereof
    Publication number: 20140342920
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods of classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the same for a mutation in one or more biomarkers.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 20, 2014
    Applicant: British Columbia Cancer Agency Branch
    Inventors: Ryan D. Morin, Marco A. Marra, Andrew J. Mungall, Martin Hirst, Maria Mendez-Lago, Randy D. Gascoyne, Joseph M. Connors
  • Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
    Publication number: 20140024099
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 23, 2014
    Inventors: Ryan D. Morin, Marco A. Marra, Randy D. Gascoyne, Joseph M. Connors
  • BIOMARKERS FOR NON-HODGKIN LYMPHOMAS AND USES THEREOF
    Publication number: 20130102477
    Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
    Type: Application
    Filed: June 23, 2011
    Publication date: April 25, 2013
    Inventors: Ryan D. Morin, Marco A. Marra, Andrew J. Mungall, Martin Hirst, Maria Mendez-Lago, Randy D. Gascoyne, Joseph M. Connors
  • SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA
    Publication number: 20110195064
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients.
    Type: Application
    Filed: June 5, 2009
    Publication date: August 11, 2011
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Arizona Bloard of Regents on behalf of the University of Arizona, Queen Mary and Westfiled College, University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic, Universitat De Barcelona, British Columbia Cancer Agency Branch, Julius-Mazimilians-University of Wuerzburg
    Inventors: Lisa Rimsza, Andrew T. Lister, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott